Clinical Trials Logo

Filter by:
NCT ID: NCT05101473 Completed - Diabetic Foot Ulcer Clinical Trials

Exercise Therapy for People With a Diabetic Foot Ulcer - a Feasibility Study

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aim of this feasibility study is to evaluate a 12-week exercise intervention in people with an active diabetic foot ulcer through pre-defined research progression criteria (participant recruitment and retention, duration of the collection of outcome measures, adherence to the exercise programme, and adverse events), besides participant and physiotherapist feedback, self-reported outcomes and objective measurements in preparation for a potential future RCT. The primary study hypothesis is that exercise therapy for people with an active diabetic foot ulcer will have high participant recruitment and adherence to treatment and that it does not affect wound healing negatively.

NCT ID: NCT05099640 Completed - Phenylketonuria Clinical Trials

A Study of PTC923 in Participants With Phenylketonuria

Start date: September 30, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of this trial is to evaluate the efficacy of PTC923 in reducing blood phenylalanine (Phe) levels in participants with phenylketonuria as measured by mean change in blood Phe levels from baseline to Weeks 5 and 6 (that is, the average of each respective treatment dose 2-week period of double-blind treatment).

NCT ID: NCT05095077 Completed - Fecal Incontinence Clinical Trials

Effects of Single Dose Tadalafil on Urethral and Anal Closure Function

Start date: August 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the trial is to assess the effect of tadalafil compared to placebo (inactive comparator) on the urethral - and anal pressure and on urine flow in healthy females. Further, the purpose of the trial is to evaluate the potential for going forward with studies of tadalafil in patients suffering from urine or fecal incontinence.

NCT ID: NCT05093582 Completed - Cluster Headache Clinical Trials

The Effects of Levcromakalim in Patients With Cluster Headache

Start date: June 4, 2021
Phase: N/A
Study type: Interventional

Cluster headache is a primary headache disorder characterized by attacks of unilateral headache of short duration and severe pain intensity. There is an unmet need to understand the underlying disease mechanisms that will ultimately lead to the development of disease-specific medicines. Until now, it has been suggested that the calcitonin gene-related peptide (CGRP) plays a major role in the initiation of a cluster headache attack, possibly involving the ATP-sensitive potassium channels. The current study aims to determine whether the opening of ATP-sensitive potassium channels triggers cluster headache attacks in patients with cluster headache.

NCT ID: NCT05087485 Completed - Melanoma Clinical Trials

Integrated Basic Science Within the Instructional Design of Pattern Recognition Training

AISC-ISF
Start date: July 10, 2021
Phase: N/A
Study type: Interventional

Investigators hypothesize that the introduction of basic science explanations within the instructional design of case-based training in visual diagnostics will improve students' learning curves, retention, and retrieval of knowledge/skill following a washout period. Research question: In a group of medical students with limited dermatological training, what is the effect of integrating biomedical causal explanations of visual criteria during a prolonged case-based skin cancer training program in visual pattern recognition when compared with an identical instructional design without biomedical explanations? How will the displacement of students' cognitive resources from practicing pattern recognition towards understanding the pattern, affect their learning behavior, learning curve (accuracy and time per diagnosis), and retrieval of pattern recognition skills following a washout period? The above-mentioned research questions will be tested through a randomized trial with an allocation ratio of 1:1. All participants will be trained in skin cancer diagnostics through a mobile application that offers simulation training and learning through written modules about the various differential diagnoses. Approximately half of the participants will be subject to a written content that displays the dermoscopic visual criteria without an explanation while the remaining half will be subject to the dermoscopic criteria + an explanation of the underlying cause. The training program consists of 500 training cases, a 14 day wash-out period, and a final training session of 100 cases.

NCT ID: NCT05087082 Completed - Telemedicine Clinical Trials

Early Transfer of Hospitalized Patients Incl. COVID-19 to a Virtual Hospital at Home Model - a Clinical Feasibility Study

Influenz-er
Start date: April 20, 2022
Phase: N/A
Study type: Interventional

This study will be part of a larger, 'virtual hospital-at-home' (vHaH) project called Influenz-er. vHaH is a care model designed to deliver medical care in the home, as a substitute for a continued inpatient hospital admission. This study will be a clinical feasibility study, which will be used to guide the framing and design of the final telemedicine supported vHaH model for hospitalized patients.

NCT ID: NCT05086809 Completed - Hearing Loss Clinical Trials

Investigation of an Updated Bone-anchored Sound Processor

Start date: September 30, 2021
Phase: N/A
Study type: Interventional

The study is a prospective, single-center, comparative, cross-over study with within-subject control design. In the investigation an updated sound processor will be tested at compared to the CE marked Ponto 3 SuperPower sound processor (available on the market since December 2016) in order to establish marketing claim(s) on the updated sound processor. The performance of the two sound processors will be evaluated via speech and hearing tests, and patient reported outcomes.

NCT ID: NCT05082675 Completed - Multiple Myeloma Clinical Trials

Stem Cell Translpantation in Multiple Myeloma

Start date: September 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether autologous transplantation (using the patient's own stem cells from the blood), followed by non-myeloablative (i.e. less intense) allogeneic transplantation (where the blood stem cells from a sibling donor are used for the transplantation) improves the outcome in patients with newly diagnosed multiple myeloma.

NCT ID: NCT05078762 Completed - Virtual Reality Clinical Trials

Immersive Virtual Reality in Simulation-based Bronchoscopy Training

Start date: October 4, 2021
Phase: N/A
Study type: Interventional

The purpose of this single-center randomized study is to investigate whether bronchoscopy training in an immersive Virtual Reality (iVR) environment will make the surgeon better at handling distractions and increase the quality of the bronchoscopy. The participants will be stratified according to gender and randomized into two groups. Both groups will initially train on the bronchoscopy simulator without VR. Afterwards the intervention group will train in an iVR environment with Virtual Reality Goggles while using the bronchoscopy simulator, while the control group will train without VR goggles. Afterwards both groups will be tested in the iVR environment in a test scenario

NCT ID: NCT05076435 Completed - Sepsis Clinical Trials

Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients

REFACED Sepsis
Start date: November 3, 2021
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, multicenter, randomized, parallel-group, open-labeled, feasibility trial investigating volumes of fluid within 24 hours in 124 patients with sepsis allocated to two different IV fluid regimens enrolled at three emergency departments in Central Region Denmark. The primary outcome is total intravenous, crystalloid fluid volume within 24 hours and key secondary outcomes include protocol violations, total fluids (intravenous and oral) within 24 hours, SAEs/SUSARs, and inhospital-, 30- and 90-day mortality.